Unverified50% confidenceOpinionExact time
AI mainly compresses the early-stage exploration cost of drug R&D (from years to months), rather than the entire R&D cycle; subsequently, cell experiments, animal experiments and multiple phases of clinical trials are still required, and the overall success rate remains very low.
1
Sources
50%
Confidence
Medium-term (~90 days)
Relevance
10/15/2026
First Seen
Valid until: 1/13/2027
Sources
Related Entities
Related Claims
UnverifiedAI的介入已被证明可将早期药物研发周期缩短40%-60%76% similarUnverifiedAI漏洞扫描的价值会随时间下降，但下降速度慢于模型价格的降幅（在同等能力水平下）68% similarUnverifiedAI生成假设的边际成本趋近于零，而实验验证成本受湿实验室物理约束无法同步降低，形成验证瓶颈67% similarUnverifiedRandomized trials, controlled implementation studies, and interrupted time series are not new in academia, but in the actual evaluation of medical AI, their frequency of use is far lower than simple predictive performance reporting and before-and-after comparisons.66% similarUnverifiedCompared with the initial baseline approach, Discovery AI reduced query cost by 90%, cut the number of input tokens by 93%, and reduced latency by 75%.65% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/1033049API
curl https://kongchang.com/api/v1/knowledge/claims/1033049MCP
get_claim(id=1033049)